Daily Briefing · Issue №104 · 2026-08-26

Physicians

Regenxbio gene therapy refiling plan derailed by FDA hold over spine MRI findings

• The FDA has put a clinical hold on Regenxbio’s RGX-121 over asymptomatic spine MRI findings, derailing the biotech’s plans to refile for approval of the once-rejected gene therapy candidate.

FierceBiotech ↗

Health OS

Fullspan Health’s AI agent sees strong early traction with 1.1M views since June launch

• The conversational AI tool—dubbed Healthline AI—is sourced directly from the publisher’s medically reviewed properties.

Fierce Healthcare ↗